(9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study ...

Morrison and Fulton have a long and storied history on the football field. This year, the conference rivals are coming ...

One doctor told Straight Arrow education and outreach are needed to ensure people understand their options and follow up on ...

On October 10, Akeso announced that the first patient had been dosed in COMPASSION-40, a Phase III study of cadonilimab as a ...

Phase III trial of cadonilimab begins in perioperative colon cancer, testing dual PD-1/CTLA-4 blockade in MSI-H/dMMR patients ...

Akeso, Inc. announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1 ...

The FDA has approved atezolizumab with chemotherapy after surgery for stage III colon cancer with deficient mismatch repair, ...

Colorectal cancer most often spreads to the liver. When those liver tumors (called liver metastases) can be removed with ...

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq) in combination with ...

Mayo Clinic says tt three years, 86.3% of patients who received immunotherapy plus chemotherapy were alive and free of ...

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for ...